Related references
Note: Only part of the references are listed.21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient
Ian J. Neeland et al.
JACC-CARDIOVASCULAR IMAGING (2021)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
Tamique Mason et al.
JACC-CARDIOVASCULAR IMAGING (2021)
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
Shigenori Hiruma et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease JACC State-of-the-Art Review
Salva R. Yurista et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure A Multimodality Study
Carlos G. Santos-Gallego et al.
JACC-CARDIOVASCULAR IMAGING (2021)
Echocardiographic Epicardial Adipose Tissue Thickness for Risk Stratification of Patients With Heart Failure
Valentina Parisi et al.
FRONTIERS IN PHYSIOLOGY (2020)
Inflammation in Heart Failure JACC State-of-the-Art Review
Sean P. Murphy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the Cardiac Benefits of Empagliflozin Independent of its Hypoglycemic Activity?
Carlos G. Santos-Gallego et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes
Fumika Shigiyama et al.
DIABETES THERAPY (2019)
Myocardial Tissue Characterization and Fibrosis by Imaging
Theodoros D. Karamitsos et al.
JACC-Cardiovascular Imaging (2019)
Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk
Alexandra C. Villasante Fricke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
Jung-Chi Hsu et al.
SCIENTIFIC REPORTS (2019)
Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis
Eric Y. Yang et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2019)
Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors
Adina Braha et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Takao Sato et al.
CARDIOVASCULAR DIABETOLOGY (2018)
The optimal anatomic site for a single slice to estimate the total volume of visceral adipose tissue by using the quantitative computed tomography (QCT) in Chinese population
X. Cheng et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2018)
Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium
Milton Packer
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis
Thomas A. Treibel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
Shusuke Yagi et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
Masaru Obokata et al.
CIRCULATION (2017)
Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic Denervation in Patients With Heart Failure
Valentina Parisi et al.
CIRCULATION RESEARCH (2016)
Predictors of New-Onset Heart Failure Differences in Preserved Versus Reduced Ejection Fraction
Jennifer E. Ho et al.
CIRCULATION-HEART FAILURE (2013)
Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement
James C. Moon et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2013)
Secretory Products From Epicardial Adipose Tissue of Patients With Type 2 Diabetes Mellitus Induce Cardiomyocyte Dysfunction
Sabrina Greulich et al.
CIRCULATION (2012)
Share Paper
